OMCL

OmnicellA

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$45.00

Analysis reference price unavailable

Analysis 2026-09-11 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$36.00

Analysis reference price unavailable

Analysis 2026-09-11 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$24.00

Analysis reference price unavailable

Analysis 2026-09-11 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-11

AI commentary

Primary-source earnings evidence is modestly positive on revenue growth and raised profitability guidance, but the reduced bookings floor and decision-cycle uncertainty temper the signal. The stock's $32.25 anchor is below the prices associated with the cited July and August insider transactions, although that comparison does not establish causation. Social coverage is unavailable, and the zero-valued social, options, short-interest and employee fields indicate missing evidence rather than neutral readings. Post-print analyst revisions and trusted attribution for the market reaction are also unavailable, keeping the view monitoring-oriented.

RankAlpha Sentiment Codex - 2026-09-11

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-10-31catalystImproved profitability versus bookings uncertaintyHigh impact

Second-quarter revenue increased 7% to $312 million, while non-GAAP EPS rose to $0.94 and non-GAAP EBITDA reached $67 million. Omnicell raised full-year profitability guidance, but the lower product-bookings bound was reduced because customer approvals and contracting are taking longer. The $15 million tariff refund also makes the quarter's profitability less fully repeatable [#SEC-8K-2026-07-30].

2026-12-31eventTitan XT shipment and conversion executionHigh impact

Management indicated Titan XT shipments remain on track for the second half of 2026 and highlighted its first competitive conversion win of the year. Converting the broader pipeline into recognized revenue could improve confidence, while further customer-decision delays would weaken the signal [#PR-EARNINGS-2026-07-31].

2027-06-30catalystOmniSphere commercialization milestoneHigh impact

OmniSphere ADS general availability remains targeted for the first half of 2027. Successful commercialization could expand Omnicell's cloud-connected platform and recurring-revenue opportunity, but monetization is early and management has not yet provided enough evidence to underwrite rapid adoption [#PR-EARNINGS-2026-07-31].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-11 • Updated nightlySource: Internal modelMethodology